24-Hour Crisis Hotline: (877)SAFEGBC or (877)723-3422 Mental Health & Substance Abuse Issues

6502 Nursery Drive, Suite 100
Victoria, TX 77904
(361)575-0611
(800)421-8825

Child & Adolescent Development: Overview
Resources
Basic InformationMore InformationLatest News
Health Tip: Travel Safely With a ChildShaming Overweight Kids Only Makes Things WorseFlu Shot Could Help Your Kid Avoid HospitalHealth Tip: Safety Advice for the HolidaysAccurate Diagnosis Seen With Photographs of Skin ConditionsIf Dad Has Depression, Kids Might Develop It, TooKids Still Getting Risky Painkiller After TonsillectomySport Sampling in Children Tied to More Exercise in AdolescenceMusic, Video Help Sixth-Graders Master Hands-Only CPRChildhood Spanking Could Heighten Adult Mental Health WoesHealth Tip: Prevent Germs at the Doctor's OfficeInfluenza Vaccines in Pediatric ERs Likely Cost-EffectiveCooling Down Sibling Rivalries When They Heat UpDoes All That Social Media Time Harm Young Minds?Helping Children Cope When a Mass Tragedy Strikes'Good Ole Days' Were Better for Kids' Health, Adults SayTV Ads Still Push Unhealthy Foods at KidsSchool-Based Food Co-op Tied to Improved Diets in ChildrenWorking With Your School NurseChildren of Immigrants Less Likely to be Up-to-Date on ShotsHealth Tip: Have Fun on Halloween, Despite AsthmaHelmets Too Rarely Used in Baseball and SoftballKids' High Blood Pressure Often OverlookedKeep Halloween Spooky, But SafeKids' Food Allergies, Especially to Peanuts, Are on the RiseHealth Tip: Talk To Your Kids About a TragedyHealth Tip: Defining CyberbullingASA: Botox Injections Beneficial for Migraine in ChildrenTrauma Takes a Toll on Half of U.S. KidsMedical Marijuana Won't Help Most Sick KidsScoliosis Screenings Can Help Catch Spine Problem EarlyArthritis Can Strike ChildrenPlan an Allergy-Safe Halloween for Your ChildHappier Mealtimes, Healthier Eating for KidsAAP Releases List of Often-Unnecessary TestsUSPSTF Recommends Counseling Youth on Sun Protection BehaviorChildhood Obesity Up Worldwide Almost 10-Fold Over 4 DecadesStart Skin Cancer Prevention Early, Health Experts SayHealth Tip: Getting Enough SleepSurviving Congenital Heart Disease as Child Not a Ticket to Good HealthHealth Tip: Children and Screen UseHealth Tip: Suggestions for a Healthy HalloweenMaking Halloween a Treat for Kids With DiabetesHealth Tip: Learn Symptoms of Childhood SinusitisChildhood 'Growth' Tests Not Always NecessaryMore U.S. Measles Cases From No Vaccine vs. Imported DiseaseMeasles Making a Comeback in the United StatesReassuring Kids After Another Senseless TragedyBilingual Kids Learn New Languages BetterGirls' Sports-Related Concussions May Last Twice As Long
Questions and AnswersLinks
Related Topics

ADHD: Attention Deficit Hyperactivity Disorder
Childhood Mental Disorders and Illnesses
Child Development & Parenting: Infants (0-2)
Child Development & Parenting: Early (3-7)

Direct-Acting Antivirals Approved for Children 12+ With HCV


HealthDay News
Updated: Apr 10th 2017

new article illustration

MONDAY, April 10, 2017 (HealthDay News) -- The U.S. Food and Drug Administration has approved two drugs to treat hepatitis C virus (HCV) infection in children aged 12 and older.

Sovaldi (sofosbuvir) and Harvoni (ledipasvir, sofosbuvir) are the first direct-acting antiviral treatments approved for children and adolescents with HCV, the agency said in a news release Friday.

The two approvals provide pediatric treatment options for six major genotypes of HCV: Harvoni is indicated for the treatment of pediatric patients ≥12 years or weighing ≥35 kg with HCV genotype 1, 4, 5, or 6 infection without cirrhosis or with mild cirrhosis. Sovaldi in combination with ribavirin is indicated for the treatment of pediatric patients ≥12 years or weighing ≥35 kg with HCV genotype 2 or 3 infection without cirrhosis or with mild cirrhosis.

In clinical studies, the most common side effects of both drugs were fatigue and headache. Health care professionals should screen all patients for evidence of current or prior hepatitis B virus infection before starting treatment with Harvoni or Sovaldi, the agency advised.

"These approvals will help change the landscape for HCV treatment by addressing an unmet need in children and adolescents," Edward Cox, M.D., director of the Office of Antimicrobial Products in the FDA's Center for Drug Evaluation and Research, said in a statement.

Harvoni and Sovaldi are marketed by Gilead Sciences, in Foster City, Calif.

More Information